Symbols / DYAI Stock $0.72 +4.96% Dyadic International, Inc.

Healthcare • Biotechnology • United States • NCM
DYAI (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Mark A. Emalfarb
Exch · Country NCM · United States
Market Cap 26.38M
Enterprise Value 24.58M
Income -7.29M
Sales 3.81M
FCF (ttm) -4.10M
Book/sh -0.01
Cash/sh 0.15
Employees 5
Insider 10d —
IPO Jan 16, 2008
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.26
PEG —
P/S 6.93
P/B -65.81
P/C —
EV/EBITDA —
EV/Sales 6.45
Quick Ratio 2.08
Current Ratio 2.42
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.21
EPS next Y -0.32
EPS Growth —
Revenue Growth 182.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-12
Earnings (prior) 2026-05-13
ROA -56.22%
ROE -28.27%
ROIC —
Gross Margin 26.10%
Oper. Margin -172.13%
Profit Margin -191.50%
Shs Outstand 36.44M
Shs Float 27.37M
Insider Own 25.53%
Instit Own 14.96%
Short Float 0.24%
Short Ratio 1.01
Short Interest 72.83K
52W High 1.35
vs 52W High -46.38%
52W Low 0.65
vs 52W Low 11.37%
Beta —
Impl. Vol. 10.25%
Rel Volume 0.51
Avg Volume 244.03K
Volume 124.99K
Target (mean) $6.00
Tgt Median $6.00
Tgt Low $5.00
Tgt High $7.00
# Analysts 2
Recom Strong_buy
Prev Close $0.69
Price $0.72
Change 4.96%
About

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.00
Mean price target
2. Current target
$0.72
Latest analyst target
3. DCF / Fair value
$-2.03
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.72
Low
$5.00
High
$7.00
Mean
$6.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-11-14 reit HC Wainwright & Co. Buy → Buy $6
2024-07-08 reit HC Wainwright & Co. Buy → Buy $6
2023-11-13 reit HC Wainwright & Co. Buy → Buy $6
2023-05-24 reit HC Wainwright & Co. Buy → Buy $6
2023-02-03 reit HC Wainwright & Co. — → Buy $6
2022-07-18 down Dawson James Buy → Neutral —
2022-04-05 main HC Wainwright & Co. — → Buy $6
2021-12-17 init HC Wainwright & Co. — → Buy $7
News
RSS: Latest DYAI news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-02 KAYE JACK Director — 21,552 — —
2026-01-02 LUCY PATRICK K Director — 21,552 — —
2026-01-02 HERBST SETH J. M.D. Director — 21,552 — —
2026-01-02 EMALFARB MARK A Chief Executive Officer — 102,609 $0.00 $0
2026-01-02 RAWSON PING WANG Chief Financial Officer — 29,158 $0.00 $0
2026-01-02 TCHELET RONEN Officer — 18,064 $0.00 $0
2026-01-02 HAZELTON JOSEPH P President — 36,418 $0.00 $0
2025-08-01 HAZELTON JOSEPH P President — 26,000 $0.95 $24,700
2025-06-20 TARNOK MICHAEL P Director — 10,776 — —
2025-06-20 BOSE ARINDAM Director — 10,776 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1.23
-64.74%
3.50
+20.58%
2.90
-1.07%
2.93
Operating Revenue
1.23
-64.74%
3.50
+20.58%
2.90
-1.07%
2.93
Cost Of Revenue
2.32
+94.19%
1.19
-39.54%
1.98
-6.94%
2.12
Reconciled Cost Of Revenue
2.32
+94.19%
1.19
-39.54%
1.98
-6.94%
2.12
Gross Profit
-1.09
-147.27%
2.30
+149.28%
0.92
+14.35%
0.81
Operating Expense
6.06
-25.93%
8.18
-10.26%
9.11
-16.56%
10.92
Research And Development
2.15
+5.40%
2.04
-38.00%
3.30
-26.75%
4.50
Selling General And Administration
5.76
-6.08%
6.13
+5.46%
5.82
-9.41%
6.42
General And Administrative Expense
5.76
-6.08%
6.13
+5.46%
5.82
-9.41%
6.42
Other Gand A
5.76
-6.08%
6.13
+5.46%
5.82
-9.41%
6.42
Other Operating Expenses
-1.86
—
—
—
Total Expenses
8.38
-10.62%
9.37
-15.48%
11.09
-14.99%
13.05
Operating Income
-7.15
-21.57%
-5.88
+28.24%
-8.19
+19.02%
-10.12
Total Operating Income As Reported
-7.19
-21.90%
-5.90
+28.30%
-8.23
+19.04%
-10.17
EBITDA
-6.91
-28.39%
-5.38
+20.81%
-6.80
+32.82%
-10.12
Normalized EBITDA
-6.86
-26.57%
-5.42
+30.27%
-7.77
+22.76%
-10.07
EBIT
-6.91
-28.39%
-5.38
+20.81%
-6.80
+32.82%
-10.12
Total Unusual Items
-0.05
-217.01%
0.04
-95.91%
0.98
+2061.57%
-0.05
Total Unusual Items Excluding Goodwill
-0.05
-217.01%
0.04
-95.91%
0.98
+2061.57%
-0.05
Special Income Charges
0.00
-100.00%
0.06
-93.84%
1.02
0.00
Net Income
-7.36
-26.78%
-5.81
+14.51%
-6.80
+30.20%
-9.74
Pretax Income
-7.36
-26.78%
-5.81
+14.51%
-6.80
+30.20%
-9.74
Net Non Operating Interest Income Expense
-0.17
-692.03%
0.03
-93.04%
0.42
+130.95%
0.18
Interest Expense Non Operating
0.46
+6.53%
0.43
0.00
—
Net Interest Income
-0.17
-692.03%
0.03
-93.04%
0.42
+130.95%
0.18
Interest Expense
0.46
+6.53%
0.43
0.00
—
Interest Income Non Operating
0.28
-37.84%
0.46
+9.67%
0.42
+130.95%
0.18
Interest Income
0.28
-37.84%
0.46
+9.67%
0.42
+130.95%
0.18
Other Income Expense
-0.05
-217.01%
0.04
-95.91%
0.98
+389.39%
0.20
Other Non Operating Income Expenses
—
—
—
0.25
Gain On Sale Of Security
-0.05
-107.88%
-0.02
+41.27%
-0.04
+23.04%
-0.05
Gain On Sale Of Business
0.00
-100.00%
0.06
-93.84%
1.02
0.00
Tax Provision
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-7.36
-26.78%
-5.81
+14.51%
-6.80
+30.20%
-9.74
Net Income From Continuing Operation Net Minority Interest
-7.36
-26.78%
-5.81
+14.51%
-6.80
+30.20%
-9.74
Net Income From Continuing And Discontinued Operation
-7.36
-26.78%
-5.81
+14.51%
-6.80
+30.20%
-9.74
Net Income Continuous Operations
-7.36
-26.78%
-5.81
+14.51%
-6.80
+30.20%
-9.74
Normalized Income
-7.32
-25.11%
-5.85
+24.77%
-7.77
+19.73%
-9.69
Net Income Common Stockholders
-7.36
-26.78%
-5.81
+14.51%
-6.80
+30.20%
-9.74
Diluted EPS
—
-0.20
+16.67%
-0.24
+29.41%
-0.34
Basic EPS
—
-0.20
+16.67%
-0.24
+29.41%
-0.34
Basic Average Shares
—
29.32
+1.80%
28.80
+1.53%
28.36
Diluted Average Shares
—
29.32
+1.80%
28.80
+1.53%
28.36
Diluted NI Availto Com Stockholders
-7.36
-26.78%
-5.81
+14.51%
-6.80
+30.20%
-9.74
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
9.95
+0.16%
9.93
+20.82%
8.22
-40.06%
13.71
Current Assets
9.90
+0.70%
9.83
+21.82%
8.07
-39.89%
13.42
Cash Cash Equivalents And Short Term Investments
7.32
-20.97%
9.26
+27.54%
7.26
-42.54%
12.64
Cash And Cash Equivalents
4.62
-28.96%
6.51
-0.13%
6.52
+12.44%
5.79
Cash Equivalents
—
5.58
-14.00%
6.49
+12.51%
5.77
Cash Financial
—
0.93
+3493.74%
0.03
-3.76%
0.03
Other Short Term Investments
2.70
-2.10%
2.76
+268.38%
0.75
-89.07%
6.85
Receivables
1.13
+330.74%
0.26
-45.14%
0.48
+22.65%
0.39
Accounts Receivable
0.49
+180.32%
0.17
-57.63%
0.41
+255.61%
0.12
Other Receivables
0.60
+855.92%
0.06
+13.49%
0.06
-74.11%
0.21
Accrued Interest Receivable
0.04
+44.87%
0.02
+140.48%
0.01
-82.70%
0.06
Prepaid Assets
0.22
-27.72%
0.30
-7.54%
0.33
-16.43%
0.39
Restricted Cash
1.23
0.00
—
—
Other Current Assets
—
0.30
-7.54%
0.33
—
Total Non Current Assets
0.05
-52.17%
0.10
-32.45%
0.15
-47.76%
0.29
Net PPE
0.04
-58.21%
0.09
-34.81%
0.14
0.00
Gross PPE
0.04
-58.21%
0.09
-34.81%
0.14
0.00
Other Properties
0.04
-58.21%
0.09
-34.81%
0.14
—
Investments And Advances
—
—
0.00
-100.00%
0.28
Long Term Equity Investment
—
—
0.00
-100.00%
0.28
Other Non Current Assets
0.01
+1.36%
0.01
-0.63%
0.01
+73.07%
0.01
Total Liabilities Net Minority Interest
8.71
+16.80%
7.46
+218.71%
2.34
-10.84%
2.63
Current Liabilities
3.69
+50.62%
2.45
+8.71%
2.25
-8.04%
2.45
Payables And Accrued Expenses
1.53
+43.58%
1.06
-37.96%
1.71
-23.20%
2.23
Payables
0.85
+76.65%
0.48
-26.53%
0.66
-48.57%
1.28
Accounts Payable
0.85
+76.65%
0.48
-26.53%
0.66
-48.57%
1.28
Current Accrued Expenses
0.67
+16.12%
0.58
-45.07%
1.06
+10.69%
0.96
Pensionand Other Post Retirement Benefit Plans Current
0.40
-20.42%
0.50
—
0.58
Current Debt And Capital Lease Obligation
0.03
-36.18%
0.05
+12.88%
0.05
—
Current Capital Lease Obligation
0.03
-36.18%
0.05
+12.88%
0.05
0.00
Current Deferred Liabilities
1.73
+107.58%
0.83
+70.13%
0.49
+125.64%
0.22
Current Deferred Revenue
—
—
0.00
-100.00%
0.18
Other Current Liabilities
—
0.00
—
—
Total Non Current Liabilities Net Minority Interest
5.03
+0.28%
5.01
+5539.66%
0.09
-49.64%
0.18
Long Term Debt And Capital Lease Obligation
5.03
+0.28%
5.01
+5539.66%
0.09
0.00
Long Term Debt
5.03
+0.98%
4.98
—
—
Long Term Capital Lease Obligation
0.00
-100.00%
0.03
-61.04%
0.09
0.00
Non Current Deferred Liabilities
—
—
0.00
-100.00%
0.18
Non Current Deferred Revenue
—
—
0.00
-100.00%
0.18
Stockholders Equity
1.23
-50.11%
2.47
-57.98%
5.88
-46.98%
11.09
Common Stock Equity
1.23
-50.11%
2.47
-57.98%
5.88
-46.98%
11.09
Capital Stock
0.05
+15.09%
0.04
+2.50%
0.04
+0.61%
0.04
Common Stock
0.05
+15.09%
0.04
+2.50%
0.04
+0.61%
0.04
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
48.44
+15.09%
42.09
+2.50%
41.06
+0.61%
40.82
Ordinary Shares Number
36.19
+21.29%
29.84
+3.56%
28.81
+0.87%
28.56
Treasury Shares Number
12.25
+0.00%
12.25
+0.00%
12.25
+0.00%
12.25
Additional Paid In Capital
113.56
+5.70%
107.44
+2.28%
105.04
+1.53%
103.46
Retained Earnings
-93.45
-8.55%
-86.09
-7.24%
-80.28
-9.25%
-73.48
Treasury Stock
18.93
+0.00%
18.93
+0.00%
18.93
+0.00%
18.93
Total Equity Gross Minority Interest
1.23
-50.11%
2.47
-57.98%
5.88
-46.98%
11.09
Total Capitalization
6.26
-15.97%
7.45
+26.69%
5.88
-46.98%
11.09
Working Capital
6.21
-15.86%
7.38
+26.90%
5.82
-47.00%
10.97
Invested Capital
6.26
-15.97%
7.45
+26.69%
5.88
-46.98%
11.09
Total Debt
5.06
-0.11%
5.07
+3599.89%
0.14
0.00
Net Debt
0.40
—
—
—
Capital Lease Obligations
0.03
-61.04%
0.09
-35.10%
0.14
0.00
Net Tangible Assets
1.23
-50.11%
2.47
-57.98%
5.88
-46.98%
11.09
Tangible Book Value
1.23
-50.11%
2.47
-57.98%
5.88
-46.98%
11.09
Interest Payable
0.10
-5.01%
0.11
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-5.70
-43.46%
-3.97
+40.91%
-6.73
+16.79%
-8.08
Cash Flow From Continuing Operating Activities
-5.70
-43.46%
-3.97
+40.91%
-6.73
+16.79%
-8.08
Net Income From Continuing Operations
-7.36
-26.78%
-5.81
+14.51%
-6.80
+30.20%
-9.74
Other Non Cash Items
0.05
-22.73%
0.06
—
—
Stock Based Compensation
0.93
-17.41%
1.13
-9.47%
1.24
-34.14%
1.89
Operating Gains Losses
0.05
+222.09%
-0.04
+96.08%
-0.98
-2061.56%
0.05
Gain Loss On Investment Securities
—
—
—
—
Net Foreign Currency Exchange Gain Loss
0.05
+107.89%
0.02
-41.27%
0.04
-23.04%
0.05
Change In Working Capital
0.66
-12.42%
0.75
+626.87%
-0.14
+55.41%
-0.32
Change In Receivables
-0.86
-517.93%
0.21
+320.40%
-0.09
-97.41%
-0.05
Changes In Account Receivables
-0.85
-485.99%
0.22
+255.26%
-0.14
-69.74%
-0.08
Change In Prepaid Assets
0.08
+239.36%
0.02
-61.88%
0.06
+566.08%
-0.01
Change In Payables And Accrued Expense
0.54
+199.58%
0.18
+186.83%
-0.21
-7836.29%
-0.00
Change In Accrued Expense
0.22
-37.82%
0.36
-19.00%
0.44
+80.95%
0.25
Change In Payable
0.31
+274.52%
-0.18
+72.33%
-0.65
-162.43%
-0.25
Change In Account Payable
0.31
+274.52%
-0.18
+72.33%
-0.65
-162.43%
-0.25
Change In Other Working Capital
0.90
+159.94%
0.34
+275.19%
0.09
+135.70%
-0.26
Investing Cash Flow
0.08
+104.37%
-1.88
-125.18%
7.45
+414.44%
-2.37
Cash Flow From Continuing Investing Activities
0.08
+104.37%
-1.88
-125.18%
7.45
+414.44%
-2.37
Net Investment Purchase And Sale
0.08
+104.37%
-1.88
-125.18%
7.45
+414.44%
-2.37
Purchase Of Investment
-5.95
+18.94%
-7.34
-145.10%
-3.00
+69.64%
-9.87
Sale Of Investment
6.03
+10.38%
5.47
-47.66%
10.45
+39.28%
7.50
Gain Loss On Sale Of Business
0.00
+100.00%
-0.06
+94.01%
-1.02
0.00
Financing Cash Flow
4.96
-15.11%
5.85
0.00
-100.00%
0.54
Cash Flow From Continuing Financing Activities
4.96
-15.11%
5.85
0.00
-100.00%
0.54
Net Issuance Payments Of Debt
0.00
-100.00%
5.82
0.00
—
Issuance Of Debt
0.00
-100.00%
5.82
0.00
—
Long Term Debt Issuance
0.00
-100.00%
5.82
0.00
—
Net Long Term Debt Issuance
0.00
-100.00%
5.82
0.00
—
Net Common Stock Issuance
4.94
0.00
—
—
Proceeds From Stock Option Exercised
0.02
-0.01%
0.02
0.00
-100.00%
0.54
Changes In Cash
-0.66
-26297.74%
-0.00
-100.34%
0.72
+107.30%
-9.91
Effect Of Exchange Rate Changes
0.00
+133.49%
-0.01
-143.02%
-0.00
+94.67%
-0.04
Beginning Cash Position
6.51
-0.13%
6.52
+12.44%
5.79
-63.21%
15.75
End Cash Position
5.85
-10.04%
6.51
-0.13%
6.52
+12.44%
5.79
Free Cash Flow
-5.70
-43.46%
-3.97
+40.91%
-6.73
+16.79%
-8.08
Interest Paid Supplemental Data
0.41
+60.05%
0.26
0.00
—
Amortization Of Securities
-0.02
+65.99%
-0.07
-33.99%
-0.05
-256.95%
0.03
Change In Interest Payable
-0.01
-105.01%
0.11
0.00
—
Common Stock Issuance
4.94
0.00
—
—
Earnings Losses From Equity Investments
—
—
—
0.00
Issuance Of Capital Stock
4.94
0.00
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category